April 16, 2021 11:00 UTC
Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress
Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress April 16, 2021 11:00 UTC Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress Castle highlights its suite of skin cancer genomic tests FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, presented data on its three skin cancer gene expression profile tests at the 10th World Congress of Melanoma and 17th European Association of Dermato-
April 16, 2021 11:30 UTC
PAR Technology Celebrates Historic Partner Milestone
PAR Technology Celebrates Historic Partner Milestone April 16, 2021 11:30 UTC PAR Technology Celebrates Historic Partner Milestone -PAR’s Brink POS® Ecosystem Now Numbers More Than 200 Integration Partners- NEW HARTFORD, N.Y.--(BUSINESS WIRE)-- ParTech, Inc. (PAR), a leading global provider of point of sale (POS) software and integrated technical solutions to the restaurant and retail industries, is celebrating more than 200 Brink POS® integration partners, cementing its spot as one of the industry’s largest and most open point of sale platform. ParTech, Inc. is a wholly owned subsidiary of PAR Technology Corporation (NYSE: PAR). PAR currently has partnerships with compan
April 16, 2021 11:00 UTC
Vontier Schedules First Quarter 2021 Earnings Conference Call
Vontier Schedules First Quarter 2021 Earnings Conference Call April 16, 2021 11:00 UTC Vontier Schedules First Quarter 2021 Earnings Conference Call RALEIGH, N.C.--(BUSINESS WIRE)-- Vontier Corporation (“Vontier”) (NYSE: VNT) announced today that it will webcast its earnings conference call for the first quarter 2021 on Thursday, May 6, 2021 beginning at 8:00 a.m. ET. The earnings call and an accompanying slide presentation will be webcast on the "Investors" section of Vontier’s website, www.vontier.com, under "Events & Presentations." A replay of the webcast will be available at the same location after the conclusion of the presentation. You can access the conference
April 16, 2021 12:30 UTC
New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD) April 16, 2021 12:30 UTC New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD) -- Presentation at American Academy of Neurology’s 73rd Annual Meeting shows no new safety signals with prolonged use of UPLIZNA -- -- UPLIZNA continues to lower the rate of NMOSD attacks throughout the four-year open-label period (OLP) -- -- Results from NMOSD patient survey describe long and daunting journey to diagnosis -- DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new
April 16, 2021 12:00 UTC
New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology April 16, 2021 12:00 UTC New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology -- TEPEZZA significantly improved the clinical course of Thyroid Eye Disease (TED) in all patient subgroups, including those with more severe disease at baseline -- -- For patients in the follow-up period with data available at 51 weeks after the last dose of TEPEZZA, 67 percent had a proptosis response, 69 percent had a diplopia response and 83 percent had a
April 16, 2021 11:00 UTC
AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors
AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors April 16, 2021 11:00 UTC AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors BOSTON--(BUSINESS WIRE)-- AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company’s Board of Directors. A widely recognized clinical oncologist with a specialty in head and neck cancer, Dr. Cullen is the Marlene and Stewart Greenebaum Distinguished Professor in Oncology and director of the Program in Oncology at the University of Maryland School of Medicine. He also serves as director of

Execution time: 0.3557 seconds
Layout: desktop